Drug Profile
Research programme: antibacterials - XTL Biopharmaceuticals
Latest Information Update: 09 Oct 2008
Price :
$50
*
At a glance
- Originator XTL Biopharmaceuticals
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pseudomonal infections
Most Recent Events
- 09 Oct 2008 Discontinued - Preclinical for Pseudomonal infections in Israel (unspecified route)
- 27 Sep 2004 Suspended - Preclinical for Pseudomonal infections in Israel (unspecified route)
- 26 Sep 2003 Preclinical development for Pseudomonal infections in Israel (unspecified route)